{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:29Z","timestamp":1786997849766,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.urolonc.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T19:47:33Z","timestamp":1521402453000},"page":"306.e1-306.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does switching the bacillus Calmette-Gu\u00e9rin strain affect clinical outcome in patients with recurrent non\u2013muscle-invasive bladder cancer after initial bacillus Calmette-Gu\u00e9rin therapy?"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-5962","authenticated-orcid":false,"given":"Naoya","family":"Niwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-4958","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-0999","authenticated-orcid":false,"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.02.005_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.02.005_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib5","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2011.10894.x","article-title":"Prognostic significance of bacillus Calmette-Gu\u00e9rin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.02.005_bib7","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.02.005_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.urolonc.2018.02.005_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib11","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2008.05.045","article-title":"Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade","volume":"180","author":"Suzuki","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","article-title":"Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis","volume":"54","author":"Eichelberg","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2018.02.005_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2490-10-12","article-title":"Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study","volume":"10","author":"Matsushima","year":"2010","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2003.09.018","article-title":"Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib19","article-title":"Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy","author":"Niwa","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib20","article-title":"Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer","author":"Niwa","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.005_bib21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","article-title":"Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence","volume":"73","author":"Takeda","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2018.02.005_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2867-10-21","article-title":"BCG strain S4-Jena: an early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis","volume":"10","author":"Schwarzer","year":"2010","journal-title":"Cancer Cell Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:13:44Z","timestamp":1761041624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918300450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1078143918300450"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.02.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does switching the bacillus Calmette-Gu\u00e9rin strain affect clinical outcome in patients with recurrent non\u2013muscle-invasive bladder cancer after initial bacillus Calmette-Gu\u00e9rin therapy?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}